Inventage Lab

Inventage Lab Forward P/E

The Forward P/E Ratio of Inventage Lab (389470.KQ) as of Oct 21, 2026 is -131.70. In the previous year, Forward P/E Ratio was -65.54 — a change of 100.94% (lower).

Forward P/E

-131.70

YoY

100.94%

Last updated:

Forward P/E Ratio of Inventage Lab is 2025 -131.70 . Forward P/E Ratio of Inventage Lab was 2024 -65.54 . It decreases by 100.94% lower compared to the previous year.

The Inventage Lab Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
-67.75 KRW
Jan 1, 2020
-86.49 KRW
Jan 1, 2021
-120.15 KRW
Jan 1, 2022
-105.14 KRW
Jan 1, 2023
-41.27 KRW
Jan 1, 2024
-65.54 KRW
Jan 1, 2025
-131.70 KRW
The Inventage Lab Forward P/E history
YEARForward P/EYoY
-131.70+100.94%
-65.54+58.82%
-41.27-60.75%
-105.14-12.50%
-120.15+38.92%
-86.49+27.66%
-67.75—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

Forward P/E Ratio of Inventage Lab is -131.70 in 2025.

Forward P/E Ratio of Inventage Lab changed from -65.54 to -131.70, representing a 100.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Inventage Lab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Inventage Lab

All Key Metrics — Inventage Lab